
|Videos|June 30, 2022
What the impact of 44-week aflibercept data may mean in a real-world setting
Author(s)Sheryl Stevenson, Emily Kaiser Maharjan
David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA
2
FDA approvals in 2025: What changed and why it matters for ophthalmologists
3
What changed in glaucoma care in 2025: Surgeon perspective
4
PRIMAvera study: Central vision improvement with subretinal implant
5












































